Irinotecan hydrochloride liposome Injection Clinical Trials

4 actively recruiting trials

Also known as: Nal-IRI, duo en yi

Pipeline

Phase 1: 1Phase 3: 1Phase 4: 1

Top Sponsors

Tang-Du Hospital1
Peking University People's Hospital1
Peking University Cancer Hospital & Institute1
Luye Pharma Group Ltd.1

Indications

Cancer4
Lung Cancer2
Locally Advanced Rectal Cancer1
Relapsed Small Cell Lung Cancer1
Ewing Sarcoma1

Other4 trials

Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.

N/A

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Phase 3

Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer

Phase 4

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.